Jazz Pharmaceuticals Plc Stock Current Ratio

JAZZ Stock

USD 122.99 0.61 0.49%

Jazz Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Jazz Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Jazz Stock. The fundamental analysis module provides a way to measure Jazz Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jazz Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	Current Ratio	2.24	2.42

Current Ratio is likely to rise to 2.42 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Jazz Pharmaceuticals PLC Company Current Ratio Analysis

Jazz Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Current Ratio

Current Asset

Current Liabilities

More About Current Ratio | All Equity Analysis

Current Jazz Pharmaceuticals Current Ratio

3.16 X

Most of Jazz Pharmaceuticals' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jazz Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Jazz Current Ratio Driver Correlations

Understanding the fundamental principles of building solid financial models for Jazz Pharmaceuticals is extremely important. It helps to project a fair market value of Jazz Stock properly, considering its historical fundamentals such as Current Ratio. Since Jazz Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Jazz Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Jazz Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Common Stock	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.91	0.96	0.75	0.96	0.98	0.98	0.99	0.11	0.98	0.92	0.98	0.95	0.59	0.63	0.5	-0.88	0.91	0.65	0.96	-0.13	0.9	0.69	0.82	-0.56
Total Stockholder Equity	0.91		0.78	0.93	0.81	0.8	0.89	0.91	0.44	0.82	0.9	0.85	0.9	0.49	0.57	0.65	-0.64	0.88	0.48	0.77	-0.26	0.7	0.76	0.82	-0.45
Net Debt	0.96	0.78		0.59	0.96	0.99	0.92	0.95	-0.08	0.99	0.82	0.98	0.9	0.53	0.54	0.34	-0.96	0.85	0.62	0.97	-0.1	0.94	0.61	0.75	-0.51
Retained Earnings	0.75	0.93	0.59		0.61	0.61	0.74	0.76	0.6	0.63	0.75	0.69	0.81	0.35	0.44	0.59	-0.44	0.77	0.36	0.57	-0.39	0.48	0.73	0.71	-0.3
Accounts Payable	0.96	0.81	0.96	0.61		0.97	0.96	0.95	-0.06	0.98	0.89	0.94	0.94	0.67	0.66	0.39	-0.9	0.84	0.67	0.98	0.02	0.92	0.69	0.75	-0.64
Long Term Debt	0.98	0.8	0.99	0.61	0.97		0.95	0.96	-0.07	1.0	0.86	0.98	0.9	0.56	0.57	0.4	-0.95	0.87	0.66	0.98	-0.1	0.94	0.61	0.76	-0.54
Net Receivables	0.98	0.89	0.92	0.74	0.96	0.95		0.97	0.14	0.96	0.96	0.92	0.94	0.68	0.72	0.47	-0.83	0.88	0.72	0.96	-0.04	0.87	0.71	0.84	-0.64
Good Will	0.99	0.91	0.95	0.76	0.95	0.96	0.97		0.08	0.97	0.9	0.98	0.94	0.58	0.61	0.58	-0.89	0.9	0.68	0.94	-0.19	0.86	0.67	0.76	-0.55
Short Term Investments	0.11	0.44	-0.08	0.6	-0.06	-0.07	0.14	0.08		-0.05	0.31	-0.02	0.14	-0.04	0.18	0.19	0.32	0.22	-0.16	-0.08	-0.17	-0.07	0.5	0.48	0.05
Total Liab	0.98	0.82	0.99	0.63	0.98	1.0	0.96	0.97	-0.05		0.88	0.98	0.91	0.61	0.62	0.41	-0.94	0.87	0.69	0.99	-0.07	0.94	0.62	0.77	-0.58
Total Current Assets	0.92	0.9	0.82	0.75	0.89	0.86	0.96	0.9	0.31	0.88		0.82	0.86	0.68	0.78	0.48	-0.68	0.85	0.64	0.88	0.04	0.82	0.71	0.91	-0.65
Intangible Assets	0.98	0.85	0.98	0.69	0.94	0.98	0.92	0.98	-0.02	0.98	0.82		0.93	0.5	0.51	0.47	-0.94	0.88	0.6	0.94	-0.2	0.89	0.63	0.72	-0.48
Property Plant Equipment	0.95	0.9	0.9	0.81	0.94	0.9	0.94	0.94	0.14	0.91	0.86	0.93		0.6	0.59	0.44	-0.82	0.87	0.59	0.9	-0.18	0.81	0.77	0.74	-0.56
Current Deferred Revenue	0.59	0.49	0.53	0.35	0.67	0.56	0.68	0.58	-0.04	0.61	0.68	0.5	0.6		0.96	0.13	-0.51	0.41	0.76	0.7	0.52	0.52	0.43	0.46	-0.95
Short Term Debt	0.63	0.57	0.54	0.44	0.66	0.57	0.72	0.61	0.18	0.62	0.78	0.51	0.59	0.96		0.16	-0.45	0.48	0.72	0.7	0.5	0.55	0.48	0.63	-0.91
Common Stock	0.5	0.65	0.34	0.59	0.39	0.4	0.47	0.58	0.19	0.41	0.48	0.47	0.44	0.13	0.16		-0.32	0.62	0.35	0.32	-0.45	0.27	0.34	0.32	-0.05
Net Tangible Assets	-0.88	-0.64	-0.96	-0.44	-0.9	-0.95	-0.83	-0.89	0.32	-0.94	-0.68	-0.94	-0.82	-0.51	-0.45	-0.32		-0.76	-0.65	-0.93	0.1	-0.89	-0.46	-0.55	0.47
Capital Surpluse	0.91	0.88	0.85	0.77	0.84	0.87	0.88	0.9	0.22	0.87	0.85	0.88	0.87	0.41	0.48	0.62	-0.76		0.51	0.82	-0.26	0.86	0.71	0.83	-0.28
Deferred Long Term Liab	0.65	0.48	0.62	0.36	0.67	0.66	0.72	0.68	-0.16	0.69	0.64	0.6	0.59	0.76	0.72	0.35	-0.65	0.51		0.73	0.16	0.52	0.35	0.38	-0.73
Long Term Debt Total	0.96	0.77	0.97	0.57	0.98	0.98	0.96	0.94	-0.08	0.99	0.88	0.94	0.9	0.7	0.7	0.32	-0.93	0.82	0.73		0.05	0.93	0.61	0.76	-0.67
Short Long Term Debt	-0.13	-0.26	-0.1	-0.39	0.02	-0.1	-0.04	-0.19	-0.17	-0.07	0.04	-0.2	-0.18	0.52	0.5	-0.45	0.1	-0.26	0.16	0.05		0.05	-0.11	0.04	-0.51
Net Invested Capital	0.9	0.7	0.94	0.48	0.92	0.94	0.87	0.86	-0.07	0.94	0.82	0.89	0.81	0.52	0.55	0.27	-0.89	0.86	0.52	0.93	0.05		0.57	0.81	-0.44
Long Term Investments	0.69	0.76	0.61	0.73	0.69	0.61	0.71	0.67	0.5	0.62	0.71	0.63	0.77	0.43	0.48	0.34	-0.46	0.71	0.35	0.61	-0.11	0.57		0.7	-0.38
Net Working Capital	0.82	0.82	0.75	0.71	0.75	0.76	0.84	0.76	0.48	0.77	0.91	0.72	0.74	0.46	0.63	0.32	-0.55	0.83	0.38	0.76	0.04	0.81	0.7		-0.41
Capital Stock	-0.56	-0.45	-0.51	-0.3	-0.64	-0.54	-0.64	-0.55	0.05	-0.58	-0.65	-0.48	-0.56	-0.95	-0.91	-0.05	0.47	-0.28	-0.73	-0.67	-0.51	-0.44	-0.38	-0.41

Click cells to compare fundamentals

Jazz Current Ratio Historical Pattern

Today, most investors in Jazz Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Jazz Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Jazz Pharmaceuticals current ratio as a starting point in their analysis.

Jazz Pharmaceuticals Current Ratio

Timeline

Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).

Competition

Predict Jazz Pharmaceuticals

Current Ratio Over Time

Jazz Price To Sales Ratio

Price To Sales Ratio

1.93

At this time, Jazz Pharmaceuticals' Price To Sales Ratio is fairly stable compared to the past year.

In accordance with the recently published financial statements, Jazz Pharmaceuticals PLC has a Current Ratio of 3.16 times. This is 8.59% higher than that of the Pharmaceuticals sector and 54.86% lower than that of the Health Care industry. The current ratio for all United States stocks is 46.3% lower than that of the firm.

Jazz Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jazz Pharmaceuticals' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics of similar companies.

Jazz Pharmaceuticals is currently under evaluation in current ratio category among its peers.

Jazz Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Jazz Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Jazz Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Jazz Fundamentals

	Return On Equity	0.12
	Return On Asset	0.0462
	Profit Margin	0.12 %
	Operating Margin	0.25 %
	Current Valuation	10.88 B
	Shares Outstanding	60.45 M
	Shares Owned By Insiders	2.93 %
	Shares Owned By Institutions	98.74 %
	Number Of Shares Shorted	4.25 M
	Price To Earning	35.18 X
	Price To Book	1.75 X
	Price To Sales	1.87 X
	Revenue	3.83 B
	Gross Profit	3.39 B
	EBITDA	1.29 B
	Net Income	414.83 M
	Cash And Equivalents	899.36 M
	Cash Per Share	14.28 X
	Total Debt	5.79 B
	Debt To Equity	2.12 %
	Current Ratio	3.16 X
	Book Value Per Share	69.01 X
	Cash Flow From Operations	1.09 B
	Short Ratio	6.16 X
	Earnings Per Share	7.23 X
	Price To Earnings To Growth	0.83 X
	Target Price	179.89
	Number Of Employees	2.8 K
	Beta	0.57
	Market Capitalization	7.47 B
	Total Asset	11.39 B
	Retained Earnings	878.66 M
	Working Capital	1.9 B
	Current Asset	1.26 B
	Current Liabilities	226.64 M
	Net Asset	11.39 B

About Jazz Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Jazz Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC